India, June 27 -- Kymera Therapeutics, Inc. (KYMR), a clinical-stage biopharma firm developing oral small-molecule degraders for immune-related diseases, has priced a $250.8 million underwritten public offering.
The deal includes 5,044,500 shares of common stock and 655,500 pre-funded warrants, both priced at $44.00 and $43.9999, respectively. The warrants carry a nominal exercise price of $0.0001 per share.
Underwriters have a 30-day option to purchase up to 855,000 additional shares. All securities in the offering are being sold by Kymera, and the transaction is expected to close on June 30, 2025, subject to standard closing conditions.
googletag.cmd.push(function() { googletag.display('div-gpt-ad-1568189509843-0'); });
Kymera plans t...